SEARCH

SEARCH BY CITATION

Current Awareness

  • 1. Reviews
  • Alexander S, Varaha ST, John G, Vesselle H. FLT: Measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′- [18F]fluorothymidine. Semin Nucl Med 37, 429-439 (2007)
  • Barentsz JO, Futterer JJ, Takahashi S. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients. Eur J Radiol 63, 369-372 (2007)
  • Bartels AL, Leenders KL. Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]-PKI1195 PET. Mov Disord 22, 1852-1856 (2007)
  • Brepoels L, Stroobants S. Is [18F]fluorodeoxyglucose positron emission tomography the ultimate tool for response and prognosis assessment?. Hematol Oncol Clin North Am 21, 855-869 (2007)
  • Briley-Saebo KC, Mulder WJM, Mani V, Hyafil F, Amirbekian V, Aguinaldo JGS, Fisher EA, Fayad ZA. Magnetic resonance imaging of vulnerable atherosclerotic plaques: Current imaging strategies and molecular imaging probes. J Magn Reson Imaging 26, 460-479 (2007)
  • Chan KWY, Wong WT. Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging. Coord Chem Rev 251, 2428-2451 (2007)
  • Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 37, 462-469 (2007)
  • Ferrara K, Pollard R, Bordeni M. Ultrasound microbubble contrast agents: Fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng 9, 415-447 (2007)
  • Frullano L, Meade TJ. Multimodal MRI contrast agents. J Biol Inorg Chem 12, 939-949 (2007)
  • Groves AM, Win T, Ben Haim S, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 8, 822-830 (2007)
  • Hammoud DA, Hoffman JM, Pomper MG. Molecular neuroimaging: From conventional to emerging technique. Radiology 245, 21-42 (2007)
  • Innis RB, Cunningham VJ, Delforge J, Fujita M, Giedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27, 1533-1539 (2007)
  • Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med 37, 316-331 (2007)
  • Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation 116, 1052-1061 (2007)
  • Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole. Semin Nucl Med 37, 451-461 (2007)
  • Margolis DJA, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS. Molecular imaging techniques in body imaging. Radiology 245, 333-356 (2007)
  • Mercer JR. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): Applications, limitations and potential. J Pharm Pharm Sci 10, 180-202 (2007)
  • Patil S, Biassoni L, Borgwardt L. Nuclear medicine in pediatric neurology and neurosurgery: Epilepsy and brain tumors. Semin Nucl Med 37, 357-381 (2007)
  • Quaia E. Microbubble ultrasound contrast agents: An update. Eur Radiol 17, 1995-2008 (2007)
  • Rajesh A, Coakley FV, Kurhanewicz J. 3D MR spectroscopic imaging in the evaluation of prostate cancer. Clin Radiol 62, 921-929 (2007)
  • Sandi AK, Timothy RD, Jean NT, Fabrice G, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 37, 420-428 (2007)
  • Seibyl JP, Chen W, Silverman DHS. 3,4-Dihydroxy-6-[18F]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors. Semin Nucl Med 37, 440-450 (2007)
  • Shidahara M, Ikoma Y, Kershaw J, Kimura Y, Naganawa M, Watabe H. PET kinetic analysis: Wavelet denoising of dynamic PET data with application to parametric imaging. Ann Nucl Med 21, 379-386 (2007)
  • Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. 18F-fluoroestradiol. Semin Nucl Med 37, 470-476 (2007)
  • Tilki D, Singer B, Seitz M, Stief CG, Ergun S. Molecular imaging of tumor blood vessels. Urologe A 46, 1266-1271 (2007)
  • Tse GM, Yeung DKY, King AD, Cheung HS, Yang WT. In vivo proton magnetic resonance spectroscopy of breast lesions: An update. Breast Cancer Res Treat 104, 249-255 (2007)
  • Vallabhajosula S. 18F-Labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37, 400-419 (2007)
  • Wagner HN. Nuclear medicine for all the world—from molecular imaging to molecular medicine (Moonho Lee Memorial Lecture). J Korean Med Sci 22, 595-597 (2007)
  • Wu WW, Li AD. Optically switchable nanoparticles for biological imaging. Nanomedicine 2, 523-531 (2007)
  • Contrast Agents: 3. Chemistry
  • Bartonkova H, Mashlan M, Medrik I, Jancik D, Zboril R. Magnetically modified bentonite as a possible contrast agent in MRI of gastrointestinal tract. Chem Pap 61, 413-416 (2007)
  • Bhushan KR, Tanaka E, Frangioni JV. Synthesis of conjugatable bisphosphonates for molecular imaging of large animals. Angew Chem Int Ed 46, 7969-7971 (2007)
  • Cage B, Russek SE, Shoemaker R, Barker AJ, Stoldt C, Ramachandaran V, Dalal NS. The utility of the single-molecule magnet Fe8 as a magnetic resonance imaging contrast agent over a broad range of concentration. Polyhedron 26, 2413-2419 (2007)
  • Carrera C, Digilio G, Baroni S, Burgio D, Consol S, Fedeli F, Longo D, Mortillaro A, Aime S. Synthesis and characterization of a Gd(III) based contrast agent responsive to thiol containing compounds. Dalton Trans 4980-4987 (2007)
  • Ding H, Yong KT, Roy I, Pudavar HE, Law WC, Bergey EJ, Prasad PN. Gold nanorods coated with multilayer polyelectrolyte as contrast agents for multimodal imaging. J Phys Chem C 111, 12552-12557 (2007)
  • Gerion D, Herberg J, Bok R, Gjersing E, Ramon E, Maxwell R, Kurhanewicz J, Budinger TF, Gray JW, Shuman MA, Chen FF. Paramagnetic silica-coated nanocrystals as an advanced MRI contrast agent. J Phys Chem C 111, 12542-12551 (2007)
  • Giardiello M, Lowe MP, Botta M. An esterase-activated magnetic resonance contrast agent. Chem Commun 4044-4046 (2007)
  • Gossuin Y, Gillis P, Muller RN, Hocq A. Relaxation by clustered ferritin: A model for ferritin-induced relaxation in vivo. NMR Biomed 20, 749-756 (2007)
  • Gunanathan C, Pais A, Furman-Haran E, Seger D, Eyal E, Mukhopadhyay S, Ben-David Y, Leitus G, Cohen H, Vilan A, Degani H, Milstein D. Water-soluble contrast agents targeted at the estrogen receptor for molecular magnetic resonance imaging. Bioconjug Chem 18, 1361-1365 (2007)
  • Hifumi H, Tanimoto A, Honda A, Citterio D, Suzuki K. Basic design and synthesis of sulfonated contrast agents for magnetic resonance imaging based on gadolinium complexes. Anal Sci 23, 1159-1165 (2007)
  • Huh YM, Lee ES, Lee JH, Jun YW, Kim PH, Yun CO, Kim JH, Suh JS, Cheon J. Hybrid nanoparticles for magnetic resonance imaging of target-specific viral gene delivery. Adv Mater 19, 3109-3112 (2007)
  • Jagielski N, Sharma S, Hombach V, Mailander V, Rasche V, Landfester K. Nanocapsules synthesized by miniemulsion technique for application as new contrast agent materials. Macromol Chem Phys 208, 2229-2241 (2007)
  • Jayagopal A, Russ PK, Haselton FR. Surface engineering of quantum dots for in vivo vascular imaging. Bioconjug Chem 18, 1424-1433 (2007)
  • Jocher CJ, Moore EG, Xu JD, Avedano S, Botta M, Aime S, Raymond KN. 1,2-Hydroxypyridonates as contrast agents for magnetic resonance imaging: TREN-1,2-HOPO. Inorg Chem 46, 9182-9191 (2007)
  • Kim G, Huang SW, Day KC, O'Donnell M, Agayan RR, Day MA, Kopelman R, Ashkenazi S. Indocyanine-green-embedded PEBBLEs as a contrast agent for photoacoustic imaging. J Biomed Opt 12, 044020 (2007)
  • Lee H, Yu MK, Park S, Moon S, Min JJ, Jeong YY, Kang HW, Jon S. Thermally cross-linked superparamagnetic iron oxide nanoparticles: Synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc 129, 12739-12745 (2007)
  • Li Q, Min JK, Ahn YH, Namm JH, Kim EM, Lui R, Kim HY, Ji Y, Wu HZ, Wisniewski T, Chang YT. Styryl-based compounds as potential in vivo imaging agents for β-amyloid plaques. Chembiochem 8, 1679-1687 (2007)
  • Liepold L, Anderson S, Willits D, Oltrogge L, Frank JA, Douglas T, Young M. Viral capsids as MRI contrast agents. Magn Reson Med 58, 871-879 (2007)
  • Major JL, Parigi G, Luchinat C, Meade TJ. The synthesis and in vitro testing of a zinc-activated MRI contrast agent. Proc Natl Acad Sci U S A 104, 13881-13886 (2007)
  • Oyelere AK, Chen PC, Huang XH, El-Sayed IH, El-Sayed MA. Peptide-conjugated gold nanorods for nuclear targeting. Bioconjug Chem 18, 1490-1497 (2007)
  • Perez-Mayoral E, Soler-Padros J, Negri V, Cerdan S, Ballesteros P. Synthetic approaches to heterocyclic ligands for Gd-based NM contrast agents. Molecules 12, 1771-1795 (2007)
  • Pikkemaat JA, Wegh RT, Lamerichs R, Van de Molengraaf RA, Langereis S, Burdinski D, Raymond AYF, Janssen HM, De Waal BFM, Willard NP, Meijer EW, Grull H. Dendritic PARACEST contrast agents for magnetic resonance imaging. Contrast Media Mol Imaging 2, 229-239 (2007)
  • Querol M, Bennett DG, Sotak C, Kang HW, Bogdanov A. A paramagnetic contrast agent for detecting tyrosinase activity. Chembiochem 8, 1637-1641 (2007)
  • Savelov AA, Kokorin DA, Fursova EY, Ovcharenko VI. A stable nitroxide radical as a contrast agent for magnetic resonance imaging. Dokl Chem 416, 241-243 (2007)
  • Vetterlein K, Bergmann U, Buche K, Walker M, Lehmann J, Minscheid MW, Scriba GKE, Hildebrand M. Comprehensive profiling of the complex dendrimeric contrast agent gadomer using a combined approach of CE, MS and CE-MS. Electrophoresis 28, 3088-3099 (2007)
  • Wojciechowski F, Suchy M, Li AX, Azab HA, Bartha R, Hudson RHE. A robust and convergent synthesis of dipeptide-DOTAM conjugates as chelators for lanthanide ions: New PARACEST MRI agents. Bioconjug Chem 18, 1625-1636 (2007)
  • Xu H, Regino CAS, Koyama Y, Hama Y, Gunn AJ, Bernardo M, Kobayashi H, Choyke PL, Brechbiel MW. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging. Bioconjug Chem 18, 1474-1482 (2007)
  • Yang J, Lee TI, Lee J, Lim EK, Hyung W, Lee CH, Song YJ, Suh JS, Yoon HG, Huh YM, Haam S. Synthesis of ultrasensitive magnetic resonance contrast agents for cancer imaging using PEG-fatty acid. Chem Mater 19, 3870-3876 (2007)
  • Yigit MV, Mazumdar D, Kim HK, Lee JH, Odintsov B, Lu Y. Smart “turn-on” magnetic resonance contrast agents based on aptamer-functionalized superparamagnetic iron oxide nanoparticles. Chembiochem 8, 1675-1678 (2007)
  • Zielhuis SW, Seppenwoolde JH, Bakker CJG, Jahnz U, Zonnenberg BA, Van het Schip AD, Hermink WE, Nijsen JFW. Characterization of holmium loaded alginate microspheres for multimodality imaging and therapeutic applications. J Biomed Mater Res A 82A, 892-898 (2007)
  • 4. Technique
  • Baldelli P, Bravin A, Di Maggio C, Gennaro G, Gambaccini M, Sarnelli A, Taibi A. Evaluation of the minimum iodine concentration for contrast enhanced subtraction mammography. Nucl Instrum Methods Phys Res A 580, 1115-1118 (2007)
  • Bearer EL, Falzone TL, Zhang XW, Biris O, Rasin A, Jacobs RE. Role of neuronal activity and kinesin on tract tracing by manganese-enhanced MRI (MEMRI). Neuroimage 37, S37-S46 (2007)
  • Brown SL, Freytag SO, Barton KN, Flynn MJ, Peck DJ, Dragovic AF, Jin R, Yeni YN, Fyhrie DP, Les CM, Zhu G, Kolozsvary A, Pitchford WC, Nathanson SD, Fenstermacher JD, Kim JH. Reporter gene imaging using radiographic contrast from nonradioactive iodide sequestered by the sodium-iodide symporter. Contrast Media Mol Imaging 2, 240-247 (2007)
  • Brunecker P, Villringer A, Schultze J, Nolte CH, Jungehulsing GJ, Endres M, Steinbrink J. Correcting saturation effects of the arterial input function in dynamic susceptibility contrast-enhanced MRI - A Monte Carlo simulation. Magn Reson Imaging 25, 1300-1311 (2007)
  • Buonaccorsi GA, O'Connor JPB, Caunce A, Roberts C, Cheung S, Watson Y, Davies K, Hope L, Jackson A, Jayson GC, Parker GJ. Tracer kinetic model-driven registration for dynamic contrast-enhanced MRI time-series data. Magn Reson Med 58, 1010-1019 (2007)
  • Calamante F, Vonken EJPA, Van Osch MJP. Contrast agent concentration measurements affecting quantification of bolus-tracking perfusion MRI. Magn Reson Med 58, 544-553 (2007)
  • Carlson AL, Gillenwater AM, Williams MD, El-Naggar AK, Richards-Kortum RR. Confocal microscopy and molecular-specific optical contrast agents for the detection of oral neoplasia. Technol Cancer Res Treat 6, 361-374 (2007)
  • Cashen TA, Jeong H, Shah MK, Bhatt HM, Shin W, Carr JC, Walker MT, Batjer HH, Carroll TJ. 4D radial contrast-enhanced MR angiography with sliding subtraction. Magn Reson Med 58, 962-972 (2007)
  • D'Onofrio M, Faccioli N, Malago R, Zamboni G, Mucelli RP. Standardize and compare contrast-enhanced ultrasonographic digital images obtained with different technologies: How to overcome the subjectivity. J Digit Imaging 20, 256-262 (2007)
  • Du J, Bydder M. High-resolution time-resolved contrast-enhanced MR abdominal and pulmonary angiography using a spiral-TRICKS sequence. Magn Reson Med 58, 631-635 (2007)
  • Haacke EM, Filleti CL, Gattu R, Ciulla C, Al-Bashir A, Suryanarayanan K, Li M, Latif Z, DelProposto Z, Sehgal V, Li T, Torquato V, Kanaparti R, Jiang J, Neelavalli J. New algorithm for quantifying vascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values. Magn Reson Med 58, 463-472 (2007)
  • Hansen C, Huttebrauker N, Wilkening W, Ashfaq M, Ermert H. Ultrasonographic contrast-agent imaging of sub-millimeter vessel structures with spatial compounding: In vitro analyses. Biomed Tech (Berl) 52, 274-283 (2007)
  • Hester-Reilly HJ, Shapley NC. Imaging contrast effects in alginate microbeads containing trapped droplets. J Magn Reson 188, 168-175 (2007)
  • Hong S, Rhee I, Chang YM. Signal loss in the T2-weighted magnetic resonance images by using an USPIO-particle contrast agent. J Korean Phys Soc 51, 1453-1456 (2007)
  • Hughes-Cassidy F, Chavez AD, Schlang A, Hassanein T, Gamst A, Wolfson T, Sirlin C. Superparamagnetic iron oxides and low molecular weight gadolinium chelates are synergistic for direct visualization of advanced liver fibrosis. J Magn Reson Imaging 26, 728-737 (2007)
  • Kanno I, Uesaka A, Nomiya S, Onabe H. Comparison of current and energy X-ray measurement methods in contrast media detection. Nucl Instrum Methods Phys Res A 580, 534-536 (2007)
  • Kawakami Y, Kunisada T, Sugihara S, Ono A, Nishida K, Abe N, Kawai A, Fujiwara K, Morimoto Y, Ozaki T. New approach for assessing vascular distribution within bone tumors using dynamic contrast-enhanced MRI. J Cancer Res Clin Oncol 133, 697-703 (2007)
  • Keeling SL, Bammer R, Stollberger R. Revision of the theory of tracer transport and the convolution model of dynamic contrast enhanced magnetic resonance imaging. Math Biol 55, 389-411 (2007)
  • Lasalarie JC, Serfaty JM, Carre C, Messika-Zeitoun D, Jeannot C, Schouman-Claeys E, Laissy JP. Accuracy of contrast-enhanced cine-MR sequences in the assessment of left ventricular function: Comparison with precontrast cine-MR sequences. Results of a bicentric study. Eur Radiol 17, 2838-2844 (2007)
  • Lyshchik A, Fleischer AC, Huamani J, Hallahan DE, Brissova M, Gore JC. Molecular imaging of vascular endothelial growth factor receptor 2 expression using targeted contrast-enhanced high-frequency ultrasonography. J Ultrasound Med 26, 1575-1586 (2007)
  • Mandeville JB, Leite FP, Marota JJA. Spin-echo MRI underestimates functional changes in microvascular cerebral blood plasma volume using exogenous contrast agent. Magn Reson Med 58, 769-776 (2007)
  • Medina DC, Kirkland DM, Tavazoie MF, Springer CS, Anderson SE. Na+/Ca2+-exchanger-mediated Mn2+-enhanced 1H2O MRI in hypoxic, perfused rat myocardium. Contrast Media Mol Imaging 2, 248-257 (2007)
  • Melbourne A, Atkinson D, White MJ, Collins D, Leach M, Hawkes D. Registration of dynamic contrast-enhanced MRI using a progressive principal component registration (PPCR). Phys Med Biol 52, 5147-5156 (2007)
  • Merlke EM, Dale M, Barboriak DP. Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: Prediction with a computer model. Acad Radiol 14, 795-803 (2007)
  • Mescam M, Eliat PA, Fauvel C, De Certaines JD, Bezy-Wendling J. A physiologically based pharmacokinetic model of vascular-extravascular exchanges during liver carcinogenesis: Application to MRI contrast agents. Contrast Media Mol Imaging 2, 215-228 (2007)
  • Namur J, Chapot R, Pelage JP, Wassef M, Langevin F, Labarre D, Laurent A. MR imaging detection of superparamagnetic iron oxide-loaded tris-acryl embolization microspheres. J Vasc Interv Radiol 18, 1287-1295 (2007)
  • Orth RC, Bankson J, Price R, Jackson EF. Comparison of single- and dual-tracer pharmacokinetic modeling of dynamic contrast-enhanced MRI data using low, medium, and high molecular weight contrast agents. Magn Reson Med 58, 705-716 (2007)
  • Park J, Mugler JP, Horger W, Kiefer B. Optimized T1-weighted contrast for single-slab 3D turbo spin-echo imaging with long echo trains: Application to whole-brain imaging. Magn Reson Med 58, 982-992 (2007)
  • Pauliah M, Saxena V, Haris M, Husain N, Rathore RKS, Gupta RK. Improved T1-weighted dynamic contrast-enhanced MRI to probe microvascularity and heterogeneity of human glioma. Magn Reson Imaging 25, 1292-1299 (2007)
  • Ramirez MS, Ragan DK, Kundra V, Bankson JA. Feasibility of multiple-mouse dynamic contrast-enhanced MRI. Magn Reson Med 58, 610-615 (2007)
  • Riederer SJ, Hu HH, Kruger DG, Haider CR, Campeau NG, Huston J. Intrinsic signal amplification in the application of 2D SENSE parallel imaging to 3D contrast-enhanced elliptical centric MRA and MRV. Magn Reson Med 58, 855-864 (2007)
  • Serda RE, Adolphi NL, Bisoffi M, Sillerud LO. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging 6, 277-288 (2007)
  • Silvennoinen HM, Hamberg LM, Valanne L, Hunter GJ. Increasing contrast agent concentration improves enhancement in first-pass CT perfusion. Am J Neuroradiol 28, 1299-1303 (2007)
  • Song M, Moon WK, Kim Y, Lim D, Song IC, Yoon BW. Labeling efficacy of superparamagnetic iron oxide nanoparticles to human neural stem cells: Comparison of ferumoxides, monocrystalline iron oxide, cross-linked iron oxide (CLIO)-NH2 and tat-CLIO. Korean J Radiol 8, 365-371 (2007)
  • Stoutjesdijk MJ, Veltman J, Huisman H, Karssemeijer N, Barentsz JO, Blickman JG, Boetes C. Automated analysis of contrast enhancement in breast MRI lesions using mean shift clustering for ROI selection. J Magn Reson Imaging 26, 606-614 (2007)
  • Trattnig S, Marlovits S, Gebetsroither S, Szomolanyi P, Welsch GH, Salomonowitz E, Watanabe A, Deimling M, Mamisch TC. Three-dimensional delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) for in vivo evaluation of reparative cartilage after matrix-associated autologous chondrocyte transplantation at 3.0T: Preliminary results. J Magn Reson Imaging 26, 974-982 (2007)
  • Vattoth S, Cherian J, Pandey T. Magnetic resonance angiographic demonstration of carotid-cavernous fistula using elliptical centric time resolved imaging of contrast kinetics (EC-TRICKS). Magn Reson Imaging 25, 1227-1231 (2007)
  • Wang MS, Haynor DR, Wilson GJ, Leiner T, Maki JH. Maximizing contrast-to-noise ratio in ultra-high resolution peripheral MR angiography using a blood pool agent and parallel imaging. J Magn Reson Imaging 26, 580-588 (2007)
  • Xu RZ, Wang YL, Wang XL, Jeong EK, Parker DL, Lu ZR. In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent. Exp Biol Med 232, 1081-1089 (2007)
  • 5. Experimental
  • Berkowitz BA, Roberts R, Penn JS, Gradianu M. High-resolution manganese-enhanced MRI of experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 48, 4733-4740 (2007)
  • Brurberg KG, Benjaminsen IC, Dorum LMR, Rofstad EK. Fluctuations in tumor blood perfusion assessed by dynamic contrast-enhanced MRI. Magn Reson Med 58, 473-481 (2007)
  • Cabezudo MJF, Petroianu G, Al-Ramadi B, Langer RD. Iosimenol, a new non-ionic dimeric contrast medium, does not induce immunoreactivity in the popliteal lymph node assay. Br J Radiol 80, 713-718 (2007)
  • Chen W, Tenney J, Kulkarni P, King JA. Imaging unconditioned fear response with manganese-enhanced MRI (MEMRI). Neuroimage 37, 221-229 (2007)
  • Chesnick IE, Todorov TI, Centeno JA, Newbury DE, Small JA, Potter K. Manganese-enhanced magnetic resonance microscopy of mineralization. Magn Reson Imaging 25, 1095-1104 (2007)
  • Curry JM, Bloeden E, Malloy KM, Cognetti DM, Merton DA, Goldberg BB, Keane WM, Rosen D, Pribitkin EA. Ultrasound-guided contrast-enhanced sentinel node biopsy of the head and neck in a porcine model. Otolaryngol Head Neck Surg 137, 735-741 (2007)
  • De Lussanet QG, Van Golde JCG, Beets-Tan RGH, Post MJ, Huijberts MS, Schaper NC, Kessels AGH, Van Engelshoven JMA, Backes WH. Dynamic contrast-enhanced MRI of muscle perfusion combined with MR angiography of collateral artery growth in a femoral artery ligation model. NMR Biomed 20, 717-725 (2007)
  • Ferrier MC, Sarin H, Fung SH, Schatlo B, Pluta RM, Gupta SN, Choyke PL, Oldfield EH, Thomasson D, Butman JA. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia 9, 546-555 (2007)
  • Franke RP, Fuhrmann R, Park JW, Rickert D, Hiebl B, Jung F. The effect of radiographic contrast media on the morphology of human venous endothelial cells. Clin Hemorheol Microcirc 37, 329-338 (2007)
  • Gao F, Kar S, Zhang J, Qiu B, Walczak P, Larabi M, Xue R, Frost E, Qian Z, Bulte JWM, Yang X. MRI of intravenously injected bone marrow cells homing to the site of injured arteries. NMR Biomed 20, 673-681 (2007)
  • Haapanen A, Ramadan UA, Autti T, Joensuu R, Tyynela J. In vivo MRI reveals the dynamics of pathological changes in the brains of cathepsin D-deficient mice and correlates changes in manganese-enhanced MRI with microglial activation lift. Magn Reson Imaging 25, 1024-1031 (2007)
  • Hassan M, Riley J, Chernomordk V, Smith P, Pursley R, Lee SB, Capala J, Gandjbakhche AH. Fluorescence lifetime imaging system for in vivo studies. Mol Imaging 6, 229-236 (2007)
  • Henrotte V, Muller RN, Bartholet A, Elst LV. The presence of halide salts influences the non-covalent interaction of MRI contrast agents and human serum albumin. Contrast Media Mol Imaging 2, 258-261 (2007)
  • Inoue Y, Yoshikawa K, Nomura Y, Izawa K, Shimada M, Tojo A, Ohtomo K. Gadobenate dimeglumine as a contrast agent for MRI of the mouse liver. NMR Biomed 20, 726-732 (2007)
  • Jiang Y, Tian X, Luo W, Zhou XD. Transmission electron microscopy of rabbit liver after high-intensity focused ultrasound ablation combined with ultrasound contrast agents. Adv Ther 24, 700-705 (2007)
  • Lee SM, Lee SH, Kang HY, Baek SY, Kim SM, Shin MJ. Assessment of musculoskeletal infection in rats to determine usefulness of SPIO-enhanced MRI. Am J Roentgenol 189, 542-548 (2007)
  • Liu CH, Huang SN, Cui JK, Kim YR, Farrar CT, Moskowitz MA, Rosen BR, Liu PK. MR contrast probes that trace gene transcripts for cerebral ischemia in live animals. FASEB J 21, 3004-3015 (2007)
  • McAteer MA, Sibson NR, Von zur Muhlen C, Schneider JE, Lowe AS, Warrick N, Channon KM, Anthony DC, Choudhury RP. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med 13, 1253-1258 (2007)
  • Pelled G, Bergman H, Ben-Hur T, Goelman G. Manganese-enhanced MRI in a rat model of Parkinson's disease. J Magn Reson Imaging 26, 863-870 (2007)
  • Penno E, Johansson L, Ahlstrom H, Johnsson C. Ultrasmall iron oxide particle contrast agent and MRI can be used to monitor the effect of anti-rejection treatment. Transplantation 84, 374-379 (2007)
  • Rabald S, Hagendorff A, Pfeiffer D, Zimmer HG, Deten A. Contrast enhanced echocardiographic follow-up of cardiac remodeling and function after myocardial infarction in rats. Ultrasound Med Biol 33, 1561-1571 (2007)
  • Rychak JJ, Graba J, Cheung AMY, Mystry BS, Lindner JR, Kerbel RS, Foster FS. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Mol Imaging 6, 289-296 (2007)
  • Stuber M, Gilson WD, Schar M, Kedziorek DA, Hofmann LV, Shah S, Vonken EJ, Bulte JWM, Kraitchman DL. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med 58, 1072-1077 (2007)
  • Vestvik IK, Egeland TAM, Gaustad JV, Mathiesen B, Rofstad EK. Assessment of microvascular density, extracellular volume fraction, and radiobiological hypoxia in human melanoma xenografts by dynamic contrast-enhanced MRI. J Magn Reson Imaging 26, 1033-1042 (2007)
  • Zhang L, Duan YY, Yin JK, Cui JH, Zhang Y, Cao TS. Grey scale enhancement by a new self-made contrast agent in early cirrhotic stage of rabbit liver. BMC Gastroenterol 7, 32 (2007)
  • 6. Applications
  • Baghi M, Mack MG, Wagenblast J, Hambek M, Rieger J, Bisdas S, Gstoettner W, Engels K, Vogl T, Knecht R. Iron oxide particle-enhanced magnetic resonance imaging for detection of benign lymph nodes in the head and neck: How reliable are the results?. Anticancer Res 27, 3571-3575 (2007)
  • Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SI, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 13, 4891-4896 (2007)
  • Diederichs G, Franiel T, Asbach P, Romano V, Hamm B, Rogalla P. Oral administration of intravenous contrast media: A tasty alternative to conventional oral contrast media in computed tomography (German, English Abstract). Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 179, 1061-1067 (2007)
  • Elgeti T, Abdel-Aty H, Wagner M, Busjahn A, Schulz-Menger J, Kivelitz D, Dietz R, Hamm B. Assessment of late gadolinium enhancement in nonischemic cardiomyopathy - Comparison of a fast phase-sensitive inversion recovery sequence (PSIR) and a conventional segmented 2D gradient echo recall (GRE) sequence-preliminary findings. Invest Radiol 42, 671-675 (2007)
  • Hauger O, Grenier N, Deminere C, Lasseur C, Delmas Y, Merville P, Combe C. USPIO-enhanced MR imaging of macrophage infiltration in native and transplanted kidneys: Initial results in humans. Eur Radiol 17, 2898-2907 (2007)
  • Holzapfel K, Breitwieser C, Prinz C, Rummeny EJ, Gaa J. Contrast-enhanced magnetic resonance cholangiography using gadolinium-EOB-DTPA. Preliminary experience and clinical applications (German, English Abstract). Radiologe 47, 536-544 (2007)
  • Kaufmann BA, Lewis C, Xie A, Mirza-Mohd A, Lindner JR. Detection of recent myocardial ischaemia by molecular imaging of P-selectin with targeted contrast echocardiography. Eur Heart J 28, 2011-2017 (2007)
  • Schneider G, Ballarati C, Grazioli L, Manfredi R, Thurnher S, Kroencke TJ, Taupitz M, Merlino B, Bonomo L, Shen N, Pirovano G, Kirchin MA, Spinazzi A. Gadobenate dimeglumine-enhanced MR angiography: Diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography. J Magn Reson Imaging 26, 1020-1032 (2007)
  • Molecular Imaging: 7. Carbon
  • Boutin H, Chauveau F, Thominiaux C, Kuhnast B, Gregoire MC, Jan S, Trebossen R, Dolle F, Tavitian B, Mattner F, Katsifis A. In vivo imaging of brain lesions with [11C]CLINME, a new PET radioligand of peripheral benzodiazepine receptors. Glia 55, 1459-1468 (2007)
  • Buchert R, Thiele F, Thomasius R, Wilke F, Petersen K, Brenner W, Mester J, Spies L, Clausen M. Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: Loss of transporters or artifact of tracer kinetic modelling?. J Psychopharmacol 21, 628-634 (2007)
  • Hammers A, Asselin MC, Turkheimer FE, Hinz R, Osman S, Hotton G, Brooks DJ, Duncan JS, Koepp MJ. Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine test-retest data. Neuroimage 38, 82-94 (2007)
  • Ito H, Shidahara M, Takano H, Takahashi H, Nozaki S, Suhara T. Mapping of central dopamine synthesis in man, using positron emission tomography with L-[β-11C]DOPA. Ann Nucl Med 21, 355-360 (2007)
  • Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Keopp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, Zimprich F, Joukhadar C, Gentzsch S, Dudczak R, Kletter K, Muller M, Baumgartner C. Pharmacoresistance in epilepsy: A pilot PET study with the P-glycoprotein substrate R-[11C] verapamil. Epilepsia 48, 1774-1784 (2007)
  • Logan J, Wang GJ, Telang F, Fowler JS, Alexoff D, Zabroski J, Jayne M, Hubbard B, King P, Carter P, Shea C, Xu Y, Muench L, Schlyer D, Learned-Coughlin S, Cosson V, Volkow ND, Ding YS. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: Problems and progress. Nucl Med Biol 34, 667-679 (2007)
  • Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer FO, Kapur S. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: A triple tracer PET study. Am J Psychiatry 164, 1411-1417 (2007)
  • McCarron JA, Zoghbi SS, Shetty HU, Vermeulen ES, Wikstrom HV, Ichise M, Yasuno F, Halldin C, Innis RB, Pike VW. Synthesis and initial evaluation of [11C](R)-RWAY in monkey - A new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET. Eur J Nucl Med Mol Imaging 34, 1670-1682 (2007)
  • Reeder SB, Brittain JH, Grist TM, Yen YF. Least-squares chemical shift separation for 13C metabolic imaging. J Magn Reson Imaging 26, 1145-1152 (2007)
  • Sakiyama Y, Hatano K, Kato T, Tajima T, Kawasumi Y, Ito K. Stimulation of adenosine A1 receptors decreases in vivo dopamine D1 receptor binding of [11C]SCH23390 in the cat strigtum revealed by positron emission tomography. Ann Nucl Med 21, 447-453 (2007)
  • Sakiyama Y, Hatano K, Tajima T, Kato T, Kawasumi Y, Suzuki M, Ito K. An atlas-based image registration method for dopamine receptor imaging with PET in rats. Ann Nucl Med 21, 455-462 (2007)
  • Schuitemaker A, Van Berckel BN, Kropholler MA, Kloet RW, Jonker C, Scheltens P, Lammertsma AA, Boellaard R. Evaluation of methods for generating parametric (R)-[11C]PK11195 binding images. J Cereb Blood Flow Metab 27, 1603-1615 (2007)
  • Seneca N, Cai L, Liow JS, Zoghbi SS, Gladding RL, Hong J, Pike VW, Innis RB. Brain and whole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for β-amyloid plaques. Nucl Med Biol 34, 681-689 (2007)
  • Shikano N, Nakajima S, Kotani T, Ogura M, Sagara JI, Iwamura Y, Yoshimoto M, Kubota N, Ishikawa N, Kawai K. Transport of D-[1-14C]-amino acids into Chinese hamster ovary (CHO-K1) cells: Implications for use of labeled D-amino acids as molecular imaging agents. Nucl Med Biol 34, 659-665 (2007)
  • Slifstein M, Kegeles LS, Gonzales R, Frankle WG, Xu XY, Laruelle M, Abi-Dargham A. [11C]NNC 112 selectivity for dopamine D1 and serotonin 5-HT2A receptors: A PET study in healthy human subjects. J Cereb Blood Flow Metab 27, 1733-1741 (2007)
  • Solbach C, Patt M, Reimold M, Blocher A, Dohmen BM, Bares R, Zeller KP, Machulla HJ. [11C]Vinblastine - Syntheses and preliminary imaging in cancer patients. J Pharm Pharm Sci 10, 266s-276s (2007)
  • Thees S, Neumaier B, Glatting G, Deisenhofer S, Von Arnim CAF, Reske SN, Mottaghy FM. Radiation dosimetry and biodistribution of the β-amyloid plaque imaging tracer 11C-BTA-1 in humans (German, English Abstract). Nuklearmedizin 46, 175-180 (2007)
  • Venneti S, Lopresti BJ, Wang GJ, Slagel SL, Mason NS, Mathis CA, Fischer ML, Larsen NJ, Mortimer AD, Hastings TG, Smith AD, Zigmond MJ, Suhara T, Higuchi M, Wiley CA. A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: Implications for PET imaging of microglial activation. J Neurochem 102, 2118-2131 (2007)
  • Wang M, Gao MZ, Miller KD, Sledge GW, Zheng QH. Synthesis of carbon-11 labeled biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues as new potential PET glioma tumor imaging agents. Appl Radiat Isot 65, 1152-1159 (2007)
  • 8. Fluorine
  • Basu S, Houseni M, Bural G, Chamroonat W, Udupa J, Mishra S, Alavi A. Magnetic resonance imaging based bone marrow segmentation for quantitative calculation of pure red marrow metabolism using 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography: A novel application with significant implications for combined structure-function approach. Mol Imaging Biol 9, 361-365 (2007)
  • Cai HC, Yin DZ, Zhang L, Yang XF, Xu XY, Liu WG, Zheng XS, Zhang H, Wang J, Xu YH, Cheng D, Zheng M, Han Y, Wu M, Wang Y. Preparation and biological evaluation of 2-amino-6-[18F]fluoro-9-(4-hydroxy-3-hydroxy-methylbutyl) purine (6-[18F]FPCV) as a novel PET probe for imaging HSV1-tk reporter gene expression. Nucl Med Biol 34, 717-725 (2007)
  • Chitneni SK, De Ruymaeker T, Balzarini J, Verbruggen AM, Bormans GM. Synthesis and biological evaluation of a lipophilic, fluorine-18-labeled 5-ethylnyl-2′-deoxyuridine derivative. J Label Compound Radiopharm 50, 649-655 (2007)
  • Curtet C, Carlier T, Mirallie E, Bodet-Milin C, Rousseau C, Barbet J, Kraeber-Bodere F. Prospective comparison of two γ probes for intraoperative detection of 18FDG: In vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. Eur J Nucl Med Mol Imaging 34, 1556-1562 (2007)
  • Desbree A, Rbah L, Langlois JB, Grenier D, Mastrippolito R, Pain F, Pinot L, Laniece P, Zimmer L, Gurden H. Simultaneous in vivo magnetic resonance imaging and radioactive measurements with the β-MicroProbe. Eur J Nucl Med Mol Imaging 34, 1868-1872 (2007)
  • Dissoki S, Aviv Y, Laky D, Abourbeh G, Levitzki A, Mishani E. The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-yl]-amide moiety - An EGFR putative irreversible inhibitor. Appl Radiat Isot 65, 1140-1151 (2007)
  • Dolle F, Helfenbein J, Hinnen F, Mavel S, Mincheva Z, Saba W, Schollhorn-Peyronneau MA, Valette H, Garreau L, Chalon S, Halldin C, Madelmont JC, Deloye JB, Bottlaender M, Le Gailliard J, Guilloteau D, Edmond P. One-step radiosynthesis of [18F]LBT-999: A selective radioligand for the visualization of the dopamine transporter with PET. J Label Compound Radiopharm 50, 716-723 (2007)
  • Garg S, Thopate SR, Minton RC, Black KW, Lynch AJH, Garg PK. 3-Amino-4-(2-((4[18F]fluorobenzyl)methylamino)methylphenylsulfanyl)be nzonitrile, an 18F fluorobenzyl analogue of DASB: Synthesis, in vitro binding and in vivo biodistribution studies. Bioconjug Chem 18, 1612-1618 (2007)
  • Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: A clinicopathologic study. Clin Cancer Res 13, 6369-6378 (2007)
  • Kitajima K, Nakarnoto Y, Senda M, Onishi Y, Okizuka H, Sugitnura K. Normal uptake of 18FDG in the testis: An assessment by PET/CT. Ann Nucl Med 21, 405-410 (2007)
  • Molthoff CFM, Klabbers BM, Berkhof J, Felten JT, Van Gelder M, Windhorst AD, Slotman BJ, Lammertsma AA. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: Comparison of 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol 9, 340-347 (2007)
  • Oishi M, Sumitani S, Nagasaki Y. On-off regulation of 19F magnetic resonance signals based on pH-sensitive PEGylated nanogels for potential tumor-specific smart 19F MRI probes. Bioconjug Chem 18, 1379-1382 (2007)
  • Penuelas I, Abizanda G, Garcia-Velloso MJ, Gavira JJ, Marti-Climent JM, Ecay M, Collantes M, De Jalon JAG, Garcia-Rodriguez A, Mazo M, Barba J, Richter JA, Prosper F. 18FDG metabolism in a rat model of chronic infarction - A 17-sector semiquantitative analysis. Nuklearmedizin 46, 149-154 (2007)
  • Rennen HJJM, Laverman P, Van Eerd JEM, Oyen WJG, Corstens FHM, Boerman OC. PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with 18F via hydrazone formation. Nucl Med Biol 34, 691-695 (2007)
  • Simons AL, Fath MA, Mattson DM, Smith BJ, Walsh SA, Graham MM, Hichwa RD, Buatt JM, Dornfeld K, Spitz DR. Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased (18)F-FDG uptake as determined by PET imaging. Int J Radiat Oncol Biol Phys 69, 1222-1230 (2007)
  • Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G, Picchio M, Machulla HJ, Wester HJ, Piert M. Tumor hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging 34, 1566-1575 (2007)
  • Sun L, Wu H, Pan WM, Guan YS. Positron emission tomography/computed tomography with 18F-fluorodeoxyglucose identifies tumor growth or thrombosis in the portal vein with hepatocellular carcinoma. World J Gastroenterol 13, 4529-4532 (2007)
  • Wu ZH, Li ZB, Cai WB, He L, Chin FT, Li F, Chen XY. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): Synthesis and microPET imaging of αvβ3 integrin expression. Eur J Nucl Med Mol Imaging 34, 1823-1831 (2007)
  • 9. Gallium
  • Decristoforo C, Knopp R, Von Guggenberg E, Rupprich M, Dreger T, Hess A, Virgolini I, Haubner R. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 28, 870-875 (2007)
  • Jalilian AR, Moghadam FH, Nemati A, Abedini M. Development of (67Ga)2-acetylpyridine 4,4-dimethyl thiosemicarbazone for detection of malignancies. J Label Compound Radiopharm 50, 414-415 (2007)
  • Win Z, Al-Nahhas A, Rubello D, Gross MD. Somatostatin receptor PET imaging with gallium-68 labeled peptides. Q J Nucl Med Mol Imaging 51, 244-250 (2007)
  • 10. Hydrogen
  • Cui MH, Hwang JH, Tomuta V, Dong ZC, Stein DT. Cross contamination of intramyocellular lipid signals through loss of bulk magnetic susceptibility effect differences in human muscle using 1H-MRSI at 4T. J Appl Physiol 103, 1290-1298 (2007)
  • Hojrup S, Jensen FT, Hokland S, Simonsen C, Christensen T, Frokiaer J, Pedersen M. Interobserver and within-subject variances of T2-relaxation time and 1H-metabolite ratios in the normal hippocampus. J Neuroradiol 34, 198-204 (2007)
  • Malhi GS, Ivanovski B, Wen W, Lagopoulos J, Moss K, Sachdev P. Measuring mania metabolites: A longitudinal proton spectroscopy study of hypomania. Acta Psychiatr Scand 116, 57-66 (2007)
  • Nafe R, Glienke WF, Hattingen E, Schlote WF, Lanfermann H, Zanella F. Correlation between amplification of the gene for the epidermal growth factor receptor (EGFR), data from preoperative proton-MR-spectroscopy (1HMRS) and histomorphometric data of glioblastomas. Anal Quant Cytol Histol 29, 199-207 (2007)
  • Oner O, Devrimci-Ozguven H, Oktem F, Yagmurlu B, Baskak B, Munir KM. Proton MR spectroscopy: Higher right anterior cingulate N-acetylaspartate/choline ratio in Asperger syndrome compared with healthy controls. Am J Neuroradiol 28, 1494-1498 (2007)
  • Opstad KS, Ladroue C, Bell BA, Griffiths JR, Howe FA. Linear discriminant analysis of brain tumour 1H MR spectra: A comparison of classification using whole spectra versus metabolite quantification. NMR Biomed 20, 763-770 (2007)
  • Torriani M, Thomas BJ, Bredella MA, Ouellette H. Intramyocellular lipid quantification: comparison between 3.0-and 1.5-T 1H-MRS. Magn Reson Imaging 25, 1105-1111 (2007)
  • Van der Meer RW, Doombos J, Kozerke S, Schar M, Bax JJ, Hammer S, Smit JWA, Romijn JA, Diamant M, Rijzewijk LJ, De Roos A, Lamb HJ. Metabolic imaging of myocardial triglyceride content: Reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology 245, 251-257 (2007)
  • 12. Iodine
  • Akhter N, Shiba K, Ogawa K, Kinuya S, Nakajima K, Mori H. In vivo characterization of radioiodinated (+)-2-[4-(4-iodophenyl) piperidino] cyclohexanol as a potential σ-1 receptor imaging agent. Nucl Med Biol 34, 697-702 (2007)
  • Bauwens M, Keyaerts M, Lahoutte T, Kersemans K, Caveliers V, Bossuyt A, Mertens J. Intra-individual comparison of the human biodistribution and dosimetry of the D and L isomers of 2-[123I]iodo-phenylalanine. Nucl Med Commun 28, 823-828 (2007)
  • Briat A, Slimani L, Perret P, Villemain D, Halimi S, Demongeot J, Fagret D, Ghezzi C. In vivo assessment of cardiac insulin resistance by nuclear probes using an iodinated tracer of glucose transport. Eur J Nucl Med Mol Imaging 34, 1756-1764 (2007)
  • Jalilian AR, Akhlaghi M, Mirzaii M, Aslani G, Rajamand AA, Fateh B, Kamalimoghadam K. Radiosynthesis of a 123I-labeled clorgiline derivative for MAO-A imaging. J Label Compound Radiopharm 50, 424-425 (2007)
  • Mzengeza S, Lakhrissi Y, Rosa-Neto P, Goertzen A, Aliaga A, Bedell B, Evans A. Radiosynthesis of cis-4-[124I]iodo-L-proline as a prototype probe for imaging anterograde axoplasmic transport systems using positron emission tomography (PET). J Label Compound Radiopharm 50, 636-637 (2007)
  • Pimlorr SL, Piggott M, Patterson J, Cavanagh J, Wyper DJ. SPECT imaging of the α4β2 nicotinic receptor using (5-123I)A85380. J Label Compound Radiopharm 50, 350-353 (2007)
  • Plisson C, Stehouwcr JS, Voll RJ, Howell L, Votaw JR, Owens MJ, Goodman MM. Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3β-(4′-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent. J Med Chem 50, 4553-4560 (2007)
  • Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, Hicks RJ. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA—First small animal PET results. J Pharm Pharm Sci 10, 203-211 (2007)
  • 13. Phosphorus
  • Klug G, Zwick RH, Frick M, Wolf C, Schocke MFH, Conci E, Jaschke W, Pachinger O, Metzler B. Impact of exercise capacity on myocardial high-energy phosphate metabolism - A 31-phosphorous magnetic resonance spectroscopy study. Int J Sports Med 28, 667-672 (2007)
  • 14. Technetium
  • Ak I, Gulbas Z, Ocak S, Kaya E, Alatas F, Vardareli E, Metintas M. 99mTc MIBI spect imaging in patients with lung carcinoma: Is it a functional probe of multidrug resistance genes?. J Comput Assist Tomogr 31, 795-799 (2007)
  • Cantorias MV, Howell RC, Todaro L, Cyr JE, Berndorff D, Rogers RD, Francesconi LC. MO tripeptide diastereomers (M=99/99mTc, Re): Models to identify the structure of 99mTc peptide targeted radiopharmaceuticals. Inorg Chem 46, 7326-7340 (2007)
  • Cyr JE, Pearson DA, Nelson CA, Lyons BA, Zheng Y, Bartis J, He JF, Cantorias MV, Howell RC, Francesconi LC. Isolation, characterization, and biological evaluation of syn and anti diastereomers of [99mTc] technetium depreotide: A somatostatin receptor binding tumor imaging agent. J Med Chem 50, 4295-4303 (2007)
  • Durkan K, Lambrecht FY, Unak P. Radiolabeling of bombesin-like peptide with 99mTc: 99mTc-litorin and biodistribution in rats. Bioconjug Chem 18, 1516-1520 (2007)
  • Engfeldt T, Tran T, Orlova A, Widstrom C, Feldwisch J, Abrahmsen L, Wennborg A, Karlstrom AE, Tolmachev V. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific affibody molecule. Eur J Nucl Med Mol Imaging 34, 1843-1853 (2007)
  • Gomes CMF, Welling M, Que I, Henriquez NV, Van der Pluijm G, Romeo S, Abrunhosa AJ, Botelho MF, Hogendoorn PCW, Pauwels EKJ, Cleton-Jansen AM. Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi. Eur J Nucl Med Mol Imaging 34, 1793-1803 (2007)
  • He HY, Lipowska M, Christoforou AM, Marzilli LG, Taylor AT. Initial evaluation of new 99mTc(CO)3 renal imaging agents having carboxyl-rich thioether ligands and chemical characterization of Re(CO)3 analogues. Nucl Med Biol 34, 709-716 (2007)
  • Kanayama S, Matsunari I, Kajinami K. Comparison of gated 13N ammonia PET and gated 99mTc sestamibi SPECT for quantiative analysis of global and regional left ventricular function. J Nucl Cardiol 14, 680-687 (2007)
  • Kosowicz J, Mikolajczak R, Czepczynski R, Ziemnicka K, Gryczynska M, Sowinski J. Two peptide receptor ligands 99mTc-EDDA/HYNIC-Tyr3-octreotide and 99mTc-EDDA/HYNIC-DGlu-octagastrin for scintigraphy of medullary thyroid carcinoma. Cancer Biother Radiopharm 22, 613-628 (2007)
  • Liang J, Chen HL, Zhou Y, Xie M, Xu LM, Lin GS. Kinetic analysis of 99mTc-sestamibi evaluates the protective effects by ischaemic preconditioning on ischaemic myocardium in an isolated rabbit heart. Nucl Med Commun 28, 864-869 (2007)
  • Lu J, Kong DJ, Yang Z, Yang SY, Fan WW, Jia HM, Wang XB. Preparation of 99mTc-nitrido asymmetrical heterocomplex with 4-(cyclohexylpiperazin-1-yl)-dithioformate and its biological evaluation as a potential myocardial imaging agent. Appl Radiat Isot 65, 1134-1139 (2007)
  • Maina T, Nikolopoulou A, Stathopoulou E, Galanis AS, Cordopatis P, Nock BA. [99mTc]Demotensin 5 and 6 in the NTS1-R-targeted imaging of tumours: Synthesis and preclinical results. Eur J Nucl Med Mol Imaging 34, 1804-1814 (2007)
  • Park SH, Gwon HJ, Choi SM. Preparation of 99mTc-labeled iron oxide nanoparticles for in vivo imaging in hyperthermia. Chem Lett 36, 1282-1283 (2007)
  • Roberts J, Chen B, Curtis LM, Agarwal A, Sanders PW, Zinn KR. Detection of early changes in renal function using 99mTc-MAG3 imaging in a murine model of ischemia-reperfusion injury. Am J Physiol 293, F1408-F1412 (2007)
  • Xu JY, Li QN, Li JG, Ran TC, Wu SW, Song WM, Chen SL, Li WX. Biodistribution of 99mTc-C60(OH)x in Sprague-Dawley rats after intratracheal instillation. Carbon 45, 1865-1870 (2007)
  • Yang AM, Xue JJ, Li X, Yu Y, Deng HX, Hu GY, Meng XW, Li J. Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer. Nucl Med Commun 28, 696-703 (2007)
  • Zhang JB, Yu TJ, Wang ZF, Lin Y, Wen F, Xing MM, Wang XB. Synthesis and biodistribution of two novel 99mTc nitrido dithiocarbamate complexes containing heterocyclic linkage as potential brain perfusion imaging agents. J Radioanal Nucl Chem 274, 195 (2007)
  • Zhao Y, Kuge Y, Zhao S, Morita K, Inubushi M, Strauss HW, Blankenberg FG, Tamaki N. Comparison of 99mTc-annexin A5 with 18FDG for the detection of atherosclerosis in ApoE-/- mice. Eur J Nucl Med Mol Imaging 34, 1747-1755 (2007)
  • 15. Others
  • Abulrob A, Brunette E, Slinn J, Baumann E, Stanimirovic D. In vivo time domain optical imaging of renal ischemia-reperfusion injury: Discrimination based on fluorescence lifetime. Mol Imaging 6, 304-314 (2007)
  • Adachi I, Gaemperli O, Valenta I, Schepis T, Siegrist PT, Treyer V, Burger C, Morita K, Kaufmann PA. Assessment of myocardial perfusion by dynamic 15O-labeled water PET imaging: Validation of a new fast factor analysis. J Nucl Cardiol 14, 698-705 (2007)
  • Akers W, Lesage F, Holten D, Achilefu S. In vivo resolution of multiexponential decays of multiple near-infrared molecular probes by fluorescence lifetime-gated whole-body time-resolved diffuse optical imaging. Mol Imaging 6, 237-246 (2007)
  • Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible is bioluminescent imaging of tumor cell growth? Single time point versus the dynamic measurement approach. Mol Imaging 6, 315-322 (2007)
  • Badea CT, Hedlund LW, Mackel JFB, Mao L, Rockman HA, Johnson GA. Cardiac micro-computed tomography for morphological and functional phenotyping of muscle LIM protein null mice. Mol Imaging 6, 261-268 (2007)
  • Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 104, 15549-15554 (2007)
  • Baskin JM, Prescher JA, Laughlin ST, Agard NJ, Chang PV, Miller IA, Lo A, Codelli JA, Bertozzit CR. Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci U S A 104, 16793-16797 (2007)
  • Blower PJ, Went MJ, Martin KE, Smith GE. Imaging hypoxia in vivo by controlling the electrochemistry of copper radionuclide complexes. J Label Compound Radiopharm 50, 354-359 (2007)
  • Cao Q, Cai W, Li ZB, Chen K, He L, Li HC, Hui M, Chen X. PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging 34, 1832-1842 (2007)
  • Cecic I, Chan DA, Sutphin PD, Ray P, Gambhir SS, Giaccia AJ, Gravcs EE. Oxygen sensitivity of reporter genes: Implications for preclinical imaging of tumor hypoxia. Mol Imaging 6, 219-228 (2007)
  • Dong SP, Roman M. Fluorescently labeled cellulose nanocrystals for bioimaging applications. J Am Chem Soc 129, 13810-13811 (2007)
  • Faley SL, Takahashi K, Crooke CE, Beckham JT, Tomemori T, Shappell SB, Jansen ED, Takahashi T. Bioluminescence imaging of vascular endothelial growth factor promoter activity in murine mammary tumorigenesis. Mol Imaging 6, 331-339 (2007)
  • Hsu BL, Case JA, Moser KW, Bateman TM, Cullom SJ. Reconstruction of rapidly acquired germanium-68 transmission scans for cardiac PET attenuation correction. J Nucl Cardiol 14, 706-714 (2007)
  • Jeon YH, Choi Y, Kim HJ, Kang JH, Kim CW, Jeong JM, Lee DS, Chung JK. In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination. Mol Imaging 6, 297-303 (2007)
  • Kim YM, Choi YD, Weissleder R, Tung CH. Membrane permeable esterase-activated fluorescent imaging probe. Bioorg Med Chem Lett 17, 5054-5057 (2007)
  • Mach RH, Wheeler KT. Imaging the proliferative status of tumors with PET. J Label Compound Radiopharm 50, 366-369 (2007)
  • Megens RTA, Egbrink MGAO, Cleutjens JPM, Kuijpers MJE, Schiffers PHM, Merkx M, Slaaf DW, Van Zandvoort MAMJ. Imaging collagen in intact viable healthy and atherosclerotic arteries using fluorescently labeled CNA35 and two-photon laser scanning microscopy. Mol Imaging 6, 247-260 (2007)
  • Ojogho O, Li A, Zuppan CW, Escher A. Bioluminescent mammalian cells grown in sponge matrices to monitor immune rejection. Mol Imaging 6, 323-330 (2007)
  • Pascu SI, Waghorn PA, Conry TD, Betts HM, Dilworth JR, Churchill GC, Pokrovska T, Christlieb M, Aigbirhio FI, Warren JE. Designing Zn(II) and Cu(II) derivatives as probes for in vitro fluorescence imaging. Dalton Trans 4988-4997 (2007)
  • Pressly ED, Rossin R, Hagooly A, Fukukawa KI, Messmore BW, Welch MJ, Wooley KL, Lamm MS, Hule RA, Pochan DJ, Hawker CJ. Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined 64Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules 8, 3126-3134 (2007)
  • Ratiney H, Noworolski SM, Sdika M, Srinivasan R, Henry RG, Nelson SJ, Pelletier D. Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data. MAGMA 20, 143-155 (2007)
  • Sun G, Xu J, Hagooly A, Rossin R, Li Z, Moore DA, Hawker CJ, Welch MJ, Wooley KL. Strategies for optimized radiolabeling of nanoparticles for in vivo PET imaging. Adv Mater 19, 3157-3162 (2007)
  • Svensson RU, Barnes JM, Rokhlin OW, Cohen NB, Henry MD. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: Implications for bioluminescence imaging of tumor response to therapy. Cancer Res 67, 10445-10454 (2007)
  • Tam JM, Upadhyay R, Pittet MJ, Weissleder R, Mahmood U. Improved in vivo whole-animal detection limits of green fluorescent protein-expressing tumor lines by spectral fluorescence imaging. Mol Imaging 6, 269-276 (2007)
  • Vavere AL, Lewis JS. Cu-ATSM: A radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans 4893-4902 (2007)
  • Wang Y, Sun ZD, Peng JC, Zhan LS. Bioluminescent imaging of hepatocellular carcinoma in live mice. Biotechnol Lett 29, 1665-1670 (2007)
  • Xu H, Baidoo K, Gunn AJ, Boswell CA, Milenic DE, Choyke PL, Brechbiel MW. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem 50, 4759-4765 (2007)
  • Yang SD, Kim SW, Park JH, Yu KH. Synthesis of lipophilic ammonium cations as tumor imaging agents for PET. J Label Compound Radiopharm 50, 600-601 (2007)
  • Zhang LM, Lee KC, Bhojani MS, Khan AP, Shilman A, Holland EC, Ross BD, Rehemtulla A. Molecular imaging of Akt kinase activity. Nat Med 13, 1114-1119 (2007)